These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 10919167)

  • 21. [Metastatic gastroenteropancreatic neuroendocrine tumours: 111In-pentetreotide and PET-FDG imaging].
    Serra Arbeloa P; Lancha Hernández C
    Rev Esp Med Nucl; 2008; 27(3):199-201. PubMed ID: 18570862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radio-guided surgery in neuroendocrine tumors.
    Gulec SA; Baum R
    J Surg Oncol; 2007 Sep; 96(4):309-15. PubMed ID: 17726664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Detection of a neuroendocrine differentiated cystic pancreatic lesion by gallium-68-DOTATOC-PET/CT with inconclusive MRI, CT and ultrasound diagnosis].
    Fröling V; Denecke T; Pöllinger A; Schreiter NF
    Rofo; 2010 Feb; 182(2):175-7. PubMed ID: 19998214
    [No Abstract]   [Full Text] [Related]  

  • 24. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
    Banzo J; Abós MD; Prats E; García F; Razola P
    Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
    [No Abstract]   [Full Text] [Related]  

  • 25. [Imaging of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors].
    Mure A; Lebtahi R; de Labriolle-Vaylet C; Askienazy S
    Gastroenterol Clin Biol; 1998 Oct; 22(10):809-18. PubMed ID: 9854206
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative analysis of diagnostic techniques for localization of gastrointestinal neuroendocrine tumors.
    Gibril F; Jensen RT
    Yale J Biol Med; 1997; 70(5-6):509-22. PubMed ID: 9825478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.
    Chiti A; Fanti S; Savelli G; Romeo A; Bellanova B; Rodari M; van Graafeiland BJ; Monetti N; Bombardieri E
    Eur J Nucl Med; 1998 Oct; 25(10):1396-403. PubMed ID: 9818279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Masking effect of chronic pancreatitis in the interpretation of somatostatin receptor positron emission tomography in pancreatic neuroendocrine tumors.
    Treglia G; Farchione A; Stefanelli A; Brizi MG; Larghi A; Inzani F; Rindi G; Rufini V
    Pancreas; 2013 May; 42(4):726-8. PubMed ID: 23591437
    [No Abstract]   [Full Text] [Related]  

  • 29. Localization of gastroenteropancreatic neuroendocrine tumors with 111indium-pentetreotide scintigraphy.
    Pauwels S; Leners N; Fiasse R; Jamar F
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):15-20. PubMed ID: 7992075
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
    Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
    J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differentiation of neuroendocrine tumors from other pancreatic lesions by echo-enhanced power Doppler sonography and somatostatin receptor scintigraphy.
    Rickes S; Unkrodt K; Ocran K; Neye H; Wermke W
    Pancreas; 2003 Jan; 26(1):76-81. PubMed ID: 12499921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Intraoperative isotope-controlled probe localization after somatostatin receptor scintigraphy of occult neuroendocrine tumors].
    Runkel N; Bäder M; Wiedenmann B; Buhr HJ
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1034-7. PubMed ID: 9931782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
    Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
    J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular imaging of gastroenteropancreatic neuroendocrine tumors.
    Miederer M; Weber MM; Fottner C
    Gastroenterol Clin North Am; 2010 Dec; 39(4):923-35. PubMed ID: 21093764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatostatin receptor scintigraphy of malignant somatostatinoma with indium-111-pentetreotide.
    Schillaci O; Annibale B; Scopinaro F; delle Fave G; Colella AC
    J Nucl Med; 1997 Jun; 38(6):886-7. PubMed ID: 9189135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Somatostatin receptor scintigraphy in the diagnosis of neuroendocrine gastroenteropancreatic tumors.
    Bäder M; Koppenhagen K
    Recent Results Cancer Res; 1996; 142():137-62. PubMed ID: 8893340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of (111)In-DTPA-pentetreotide scintigraphy in accurate diagnosis of neuroendocrine gastroenteropancreatic tumors.
    Ichijo T; Ishikawa M; Shimojo M; Tsubuku M; Tsuboi K; Miyachi Y
    J Hepatobiliary Pancreat Surg; 2001; 8(5):473-8. PubMed ID: 11702259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical studies of SPECT and PET tracers for NET.
    Brom M; Boerman O; Gotthardt M; Oyen WJ
    PET Clin; 2014 Jan; 9(1):63-9. PubMed ID: 25029935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re: The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours in receptor imaging.
    Adesanya O
    Clin Radiol; 2007 Jan; 62(1):92; author reply 93. PubMed ID: 17145272
    [No Abstract]   [Full Text] [Related]  

  • 40. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
    Jamar F; Fiasse R; Leners N; Pauwels S
    J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.